BIVI News and Press, BioVie Inc. From 11/03/23

HST Global Inc (HSTC) is expected to report for quarter end 2023-09-30 Air China Ltd ADR - Level I (AIRYY) is expected to report for Q3 2023 GrafTech International Ltd. (EAF) is expected to report $-0.05 for Q3 2023 Cardinal Health Inc. (CAH) is expected to report $1.4 for Q1 2024 ...

CARSON CITY, Nev., Nov. 02, 2023 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease,...

2023-10-31 13:28:44 ET Gainers: SciSparc Ltd SPRC +65% . Cardio Diagnostics Holdings ( CDIO ) +54% . Alpha Technology Group Limited ATGL +50% . Centogene ( CNTG ) +30% . Pop Culture Group Co Ltd ( CPOP ) +30% . American Acquisition O...

--News Direct-- BioVie Inc CEO Cuong Do joined Steve Darling from Proactive to share news the company will be presenting its blinded data on cognitive, biomarker, and imaging findings from the recently completed Phase 3 clinical trial of NE3107 in the treatment of mild to moderate Alzheim...

CARSON CITY, Nev., Oct. 30, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, ...

2023-10-27 08:23:45 ET Losers: PTC Therapeutics PTCT -23% after Q3 earning release . Sanofi SNY -17% after Q3 earning release . Enphase Energy ENPH -17% after Q3 earning release . Jaguar Global Growth Corp I ( JGGC ) -13%. NatWest Group ...

2023-10-26 13:48:39 ET More on BioVie, Cognition, etc. BioVie: Bullish Signals From Blinded Data Presentation (Rating Upgrade) Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise BioVie: Well-Powered Phase 3 Trial In Alzheimer's Could Greatly Be...

CARSON CITY, Nev., Oct. 26, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, ...

2023-10-26 06:54:11 ET Summary BIVI presented yesterday blinded clinical, imaging and biomarker outcome data of it phase 3 Alzheimer's Disease trial. Consistent improvements were seen in all above measures, which is suggestive of a treatment effect, as such improvements would be u...

Statistically significant population changes from baseline were observed for all primary and secondary cognitive and functional assessments measured: ADAS-Cog12, ADCS-CGIC, MMSE, CDR, CDR-SB, ADCOMS, and ADL. 1 An apparent significant reduction in amyloid burden from baseline wa...